Anti-VEGF monotherapy safe and effective for SRNVM
Intravitreal anti-VEGF monotherapy is safe and effective in treatment-naïve subretinal neovascular membrane (SRNVM) secondary to macular telangiectasia (Mactel).
Intravitreal anti-VEGF monotherapy is safe and effective in treatment-naïve subretinal neovascular membrane (SRNVM) secondary to macular telangiectasia (Mactel), claims a paper in the journal Retina.
The retrospective chart review led by Dr Raja Narayanan, L. V. Prasad Eye Institute, Hyderabad, India, included 16 eyes of 16 patients with naïve SRNVM secondary to Mactel examined between January 2007 and April 2011. Four eyes were administered intravitreal ranibizumab monotherapy and 12 were treated with intravitreal bevacizumab monotherapy.
The primary outcome was the mean change in best-corrected visual acuity (BCVA) at the final postoperative visit. Secondary outcomes included the mean number of intravitreal injections, retinal thickness on OCT and IOP. Demographic data, medical history and ocular history were also recorded.
Mean baseline visual acuity was 0.17 ± 0.16 and the mean final visual acuity was0.27 ± 0.14. No injection-related complications were reported and the mean amount of intravitreal injections was 1.9.
To read the abstract please click here.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
